Search
Invitrogen
Benvitimod Recombinant Mouse Monoclonal Antibody (4A11)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
FIGURE: 1 / 1
Benvitimod Antibody (MA566623) in SDS-PAGE
SDS-PAGE characterization of Benvitimod under reducing conditions. Lane M: Protein marker (kDa); Lane BVM: Purified Benvitimod Recombinant Monoclonal (Product # MA566623). Benvitimod showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-657.
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Product Details
MA566623
Product Specifications
Species Reactivity
Chemical
Host/Isotype
Mouse
/ IgG
Expression System
CHO cells
Class
Recombinant Monoclonal
Type
Antibody
Clone
4A11
Immunogen
Conjugate of BVM hapten and KLH.
Conjugate
Unconjugated
Unconjugated
Unconjugated
Form
Liquid
Concentration
7.1 mg/mL
Amount
200 µg
Purification
Protein G
Storage buffer
PBS
Contains
0.09% sodium azide
Storage conditions
-20°C
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
Target Information
Benvitimod is an aryl hydrocarbon receptor (AhR) immunomodulator primarily used in the treatment of psoriasis and atopic dermatitis. It functions by inhibiting the phosphorylation of STAT6, thereby preventing the downregulation of tight junction proteins induced by interleukins IL-4 and IL-13. This mechanism helps maintain skin barrier integrity and reduces inflammation. Benvitimod also impedes keratinocyte proliferation by inhibiting CDK4/6 and suppressing the JAK/STAT3 pathway, which is crucial for cell cycle progression. The drug has shown efficacy and tolerability in clinical trials, particularly for patients with mild to severe psoriasis, and has recently completed phase 3 trials. Benvitimod is applied topically, making it a convenient option for managing skin conditions with a body surface area involvement of 1-20%.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support